Suggested remit: To appraise the clinical and cost effectiveness of canagliflozin within its marketing authorisation for treating chronic kidney disease in people with type 2 diabetes. The Topic Selection Oversight Panel (TSOP) have determined that cangliflozin would be best assessed and included in the chronic kidney disease and Type 2 diabetes in adults: management update. Therefore the appraisal has been suspended from the Technology Appraisal work programme.
Suspended
- Status:
- Suspended
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1653
Project Team
- Project lead
- Danielle Lees
Email enquiries
If you have any queries please email topic.selection@nice.org.uk
Stakeholders
- Companies sponsors
- Napp Pharmaceuticals (canagliflozin)
- Others
- Department of Health and Social Care
- NHS England
- NHS Newbury and District CCG
- NHS Sheffield CCG
- Welsh Government
- Patient carer groups
- BEMDA: Black and Ethnic Minority Diabetes Association
- Black Health Agency
- Diabetes Research and Wellness Foundation
- Diabetes UK
- Heart UK
- InDependent Diabetes Trust
- INPUT
- Kidney Care UK
- Kidney Research UK
- Muslim Council of Britain
- National Kidney Federation
- Network of Sikh Organisations
- Polycystic Kidney Disease Charity
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Stroke Association
- Professional groups
- 4front
- Association for the Study of Obesity
- Association of British Clinical Diabetologists
- Association of Renal Technologists
- British and Irish Hypertension Society
- British Association for Nursing in Cardiovascular Care
- British Association of Endocrine and Thyroid Nurses
- British Geriatrics Society
- British Heart Foundation
- British Renal Society
- National Metabolic Biochemistry Network
- Primary Care Diabetes Society
- Renal Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for DGH Nephrologists
- Society for Endocrinology
- TREND UK
- UK Clinical Pharmacy Association
- UK Renal Pharmacy Group
- General commentators
- All Wales Therapeutic and Toxicology Centre
- Allied Health Professionals Federation
- Association of Renal Industries
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health, Social Services and Public Safety for Northern Ireland
- Diabetes UK Cymru
- Healthcare Improvement Scotland
- Medicines and Healthcare Products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Alliance
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Endocrine and Diabetes Society
- Welsh Health Specialised Services Committee
- Welsh Kidney Patients Association
- Relevant research groups
- Cochrane Kidney and Transplant Group
- Cochrane Metabolic & Endocrine Disorders Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
- The Society for Research in Rehabilitation
- Wellcome Trust
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 December 2020 | Note added to the project documents |
| 22 December 2020 | Suspended. Suspended |
| 07 May 2020 | Invitation to participate |
| 07 May 2020 | Schedule affected by COVID-19. Invitation to participate issued but schedule affected by COVID-19 |
| 06 April 2020 | Note added to the project documents |
| 18 November 2019 - 16 December 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual